While first-line EGFR inhibitors have revolutionized the treatment of mutant lung cancer, the inevitable development of therapeutic resistance remains a primary clinical hurdle. I ...
MEKanistic Therapeutics, a biotechnology company developing first-in-class precision medicines designed to overcome cancer resistance mechanisms, today announced that the U.S. Food and Drug ...
The RAMOSE and RELAY trials revealed the capacity and constraints of combination therapy with ramucirumab (Cyramza) in EGFR-mutated metastatic non-small cell lung cancer (NSCLC). The phase II RAMOSE ...
Uncommon EGFR mutations, such as exon 20 insertions, account for nearly one-third of EGFR-driven NSCLC, complicating treatment strategies due to their diversity and structural challenges. Traditional ...
The epidermal growth factor receptor (EGFR) inhibitors are among the most intensely studied new molecular therapeutic agents. Although response rates have been somewhat disappointing when EGFR ...
Alternative pathway blockade via factor B inhibition limits C3 cleavage, amplification loop activity, and downstream membrane ...
In a recent study published in the journal Nature Biotechnology, researchers in Switzerland used base and prime editing to create and analyze a wide array of variants of the epithelial growth factor ...
Please provide your email address to receive an email when new articles are posted on . The paper provides a race-free equation to estimate kidney filtration in adults with stable kidney function. It ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results